O
AMAG

OrbiMed’s AMAG Pharmaceuticals AMAG Stock Holding History

OrbiMed’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-275,000
Closed -$15M – 153
2015
Q1 		$15M Sell
275,000
-194,000
-41% -$9.25M 0.13% 89
2014
Q4 		$20M Buy
469,000
+311,000
+197% +$11.2M 0.19% 76
2014
Q3 		$5.04M Buy
+158,000
New +$3.37M 0.05% 112

Other funds holding AMAG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OrbiMed's AMAG Position: Q2 2015 in Review

OrbiMed sold out of AMAG Pharmaceuticals (AMAG) in Q2 2015, closing a stake of 275,000 shares — an estimated $15M sold.

OrbiMed first reported a position in AMAG in Q3 2014 and held it in 3 quarters. The position peaked at $20M in Q4 2014. 208 funds tracked by Wall St. Rank hold AMAG as of Q2 2015.

  • OrbiMed reported no remaining AMAG Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • OrbiMed sold 275,000 AMAG Pharmaceuticals shares in Q2 2015, an estimated $15M.
  • OrbiMed first reported a position in AMAG Pharmaceuticals in Q3 2014 and held it in 3 quarters.
  • OrbiMed's AMAG Pharmaceuticals position peaked at $20M in Q4 2014.
  • 208 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2015.

Based on OrbiMed's 13F filing for Q2 2015, filed 14 Aug 2015.